Cargando…

Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections

Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis throughout the world. Most infections are acute but they can become chronic in immunocompromised patients, such as solid organ transplant patients, patients with hematologic malignancy undergoing chemotherapy and those with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lhomme, Sébastien, Marion, Olivier, Abravanel, Florence, Izopet, Jacques, Kamar, Nassim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073673/
https://www.ncbi.nlm.nih.gov/pubmed/31991629
http://dx.doi.org/10.3390/jcm9020331
_version_ 1783506672508993536
author Lhomme, Sébastien
Marion, Olivier
Abravanel, Florence
Izopet, Jacques
Kamar, Nassim
author_facet Lhomme, Sébastien
Marion, Olivier
Abravanel, Florence
Izopet, Jacques
Kamar, Nassim
author_sort Lhomme, Sébastien
collection PubMed
description Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis throughout the world. Most infections are acute but they can become chronic in immunocompromised patients, such as solid organ transplant patients, patients with hematologic malignancy undergoing chemotherapy and those with a human immunodeficiency virus (HIV) infection. Extra-hepatic manifestations, especially neurological and renal diseases, have also been described. To date, four main genotypes of HEV (HEV1-4) were described. HEV1 and HEV2 only infect humans, while HEV3 and HEV4 can infect both humans and animals, like pigs, wild boar, deer and rabbits. The real epidemiology of HEV has been underestimated because most infections are asymptomatic. This review focuses on the recent advances in our understanding of the pathophysiology of acute HEV infections, including severe hepatitis in patients with pre-existing liver disease and pregnant women. It also examines the mechanisms leading to chronic infection in immunocompromised patients and extra-hepatic manifestations. Acute infections are usually self-limiting and do not require antiviral treatment. Conversely, a chronic HEV infection can be cleared by decreasing the dose of immunosuppressive drugs or by treating with ribavirin for 3 months. Nevertheless, new drugs are needed for those cases in which ribavirin treatment fails.
format Online
Article
Text
id pubmed-7073673
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70736732020-03-19 Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections Lhomme, Sébastien Marion, Olivier Abravanel, Florence Izopet, Jacques Kamar, Nassim J Clin Med Review Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis throughout the world. Most infections are acute but they can become chronic in immunocompromised patients, such as solid organ transplant patients, patients with hematologic malignancy undergoing chemotherapy and those with a human immunodeficiency virus (HIV) infection. Extra-hepatic manifestations, especially neurological and renal diseases, have also been described. To date, four main genotypes of HEV (HEV1-4) were described. HEV1 and HEV2 only infect humans, while HEV3 and HEV4 can infect both humans and animals, like pigs, wild boar, deer and rabbits. The real epidemiology of HEV has been underestimated because most infections are asymptomatic. This review focuses on the recent advances in our understanding of the pathophysiology of acute HEV infections, including severe hepatitis in patients with pre-existing liver disease and pregnant women. It also examines the mechanisms leading to chronic infection in immunocompromised patients and extra-hepatic manifestations. Acute infections are usually self-limiting and do not require antiviral treatment. Conversely, a chronic HEV infection can be cleared by decreasing the dose of immunosuppressive drugs or by treating with ribavirin for 3 months. Nevertheless, new drugs are needed for those cases in which ribavirin treatment fails. MDPI 2020-01-24 /pmc/articles/PMC7073673/ /pubmed/31991629 http://dx.doi.org/10.3390/jcm9020331 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lhomme, Sébastien
Marion, Olivier
Abravanel, Florence
Izopet, Jacques
Kamar, Nassim
Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections
title Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections
title_full Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections
title_fullStr Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections
title_full_unstemmed Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections
title_short Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections
title_sort clinical manifestations, pathogenesis and treatment of hepatitis e virus infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073673/
https://www.ncbi.nlm.nih.gov/pubmed/31991629
http://dx.doi.org/10.3390/jcm9020331
work_keys_str_mv AT lhommesebastien clinicalmanifestationspathogenesisandtreatmentofhepatitisevirusinfections
AT marionolivier clinicalmanifestationspathogenesisandtreatmentofhepatitisevirusinfections
AT abravanelflorence clinicalmanifestationspathogenesisandtreatmentofhepatitisevirusinfections
AT izopetjacques clinicalmanifestationspathogenesisandtreatmentofhepatitisevirusinfections
AT kamarnassim clinicalmanifestationspathogenesisandtreatmentofhepatitisevirusinfections